COMMUNITY LEVEL SURVEY BURDEN ESTIMATE—Continued

<table>
<thead>
<tr>
<th>Survey section</th>
<th>Content description</th>
<th>Number of respondents</th>
<th>Number of responses</th>
<th>Hourly burden/response</th>
<th>Total hourly burden</th>
</tr>
</thead>
<tbody>
<tr>
<td>172–178</td>
<td>Contextual Factors and Closing Questions, Intervention Specific Information and Adaptations, Intervention Outcomes</td>
<td>390</td>
<td>2</td>
<td>1.0</td>
<td>780</td>
</tr>
<tr>
<td>Part II, 1–52</td>
<td></td>
<td>390</td>
<td>3</td>
<td>2.0</td>
<td>2,340</td>
</tr>
<tr>
<td>53–60</td>
<td></td>
<td>390</td>
<td>6</td>
<td>1.0</td>
<td>2,340</td>
</tr>
<tr>
<td>Sub-forms</td>
<td>Intervention Component Information</td>
<td>390</td>
<td>6</td>
<td>1.0</td>
<td>2,340</td>
</tr>
<tr>
<td>Review of past responses</td>
<td></td>
<td>390</td>
<td>2</td>
<td>1.0</td>
<td>780</td>
</tr>
<tr>
<td>Total Community Level Year 3 Burden.</td>
<td></td>
<td>24</td>
<td>7.9</td>
<td>10,062</td>
<td></td>
</tr>
<tr>
<td>Average Annual Community Burden.</td>
<td></td>
<td>21</td>
<td>8.1</td>
<td>8,827</td>
<td></td>
</tr>
</tbody>
</table>

Send comments to Summer King, SAMHSA Reports Clearance Officer, Room 71–1044, One Choke Cherry Road, Rockville, MD 20857. Written comments should be received within 60 days of this notice.

Dated: December 30, 2005.

Anna Marsh,
Director, Office of Program Services.

[FR Doc. E6–95 Filed 1–9–06; 8:45 am]

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration

Current List of Laboratories Which Meet Minimum Standards To engage in Urine Drug Testing for Federal Agencies

AGENCY: Substance Abuse and Mental Health Services Administration, HHS.

ACTION: Notice.

SUMMARY: The Department of Health and Human Services (HHS) notifies Federal agencies of the laboratories currently certified to meet the standards of Subpart C of the Mandatory Guidelines for Federal Workplace Drug Testing Programs (Mandatory Guidelines). The Mandatory Guidelines were first published in the Federal Register on April 11, 1988 (53 FR 11970), and subsequently revised in the Federal Register on June 9, 1994 (59 FR 29908), on September 30, 1997 (62 FR 51118), and on April 13, 2004 (69 FR 19644).

A notice listing all currently certified laboratories is published in the Federal Register during the first week of each month. If any laboratory’s certification is suspended or revoked, the laboratory will be omitted from subsequent lists until such time as it is restored to full certification under the Mandatory Guidelines.

If any laboratory has withdrawn from the HHS National Laboratory Certification Program (NLCP) during the past month, it will be listed at the end, and will be omitted from the monthly listing thereafter.

This notice is also available on the Internet at http://workplace.samhsa.gov and http://www.drugfreeworkplace.gov.

FOR FURTHER INFORMATION CONTACT: Mrs. Giselle Hersh or Dr. Walter Vogl, Division of Workplace Programs, SAMHSA/CSAP, Room 2–1035, 1 Choke Cherry Road, Rockville, Maryland 20857: 240–276–2600 (voice), 240–276–2610 (fax).

SUPPLEMENTARY INFORMATION: The Mandatory Guidelines were developed in accordance with Executive Order 12564 and section 503 of Public Law 100–71. Subpart C of the Mandatory Guidelines, “Certification of Laboratories Engaged in Urine Drug Testing for Federal Agencies,” sets strict standards that laboratories must meet in order to conduct drug and specimen validity tests on urine specimens for Federal agencies. To become certified, an applicant laboratory must undergo three rounds of performance testing plus an on-site inspection. To maintain that certification, a laboratory must participate in a quarterly performance testing program plus undergo periodic, on-site inspections.

Laboratories which claim to be in the applicant stage of certification are not to be considered as meeting the minimum requirements described in the HHS Mandatory Guidelines. A laboratory must have its letter of certification from HHS/SAMHSA (formerly: HHS/NIDA) which attests that it has met minimum standards.

In accordance with Subpart C of the Mandatory Guidelines dated April 13, 2004 (69 FR 19644), the following laboratories meet the minimum standards to conduct drug and specimen validity tests on urine specimens:


Baptist Medical Center-Toxicology Laboratory, 9601 I–650, Exit 7, Little Rock, AR 72205–7299. 501–202–2783. (Formerly: Forensic Toxicology Laboratory Baptist Medical Center).

Criminal Reference Lab, 8433 Quivira Road, Lenexa, KS 66215–2802. 800–445–6917.

Diagnostic Services, Inc., dba DSI, 12700 Westlinks Drive, Fort Myers, FL 33913. 239–561–6200/800–735–5416.

Doctors Laboratory, Inc., 2906 Julia Drive, Valdosta, GA 31602. 229–671–2281.

DrugScan, Inc., P.O. Box 2969, 1119 Mears Road, Warmminster, PA 19074. 215–674–9310.


General Medical Laboratories, 36 South Brooks St., Madison, WI 53715. 608−627−6225.

Kroll Scientific Testing Laboratories, Inc., 450 Southlake Blvd., Richmond, VA 23236. 804−378−9130. (Formerly: Scientific Testing Laboratories, Inc.)

Laboratory Corporation of America Holdings, 7207 N. Gessner Road, Houston, TX 77040. 713−856−8288/800−800−2387.

Laboratory Corporation of America Holdings, 69 First Ave., Raritan, NJ 08869. 908−526−2400/800−437−4986. (Formerly: Roche Biomedical Laboratories, Inc.)

Laboratory Corporation of America Holdings, 1904 Alexander Drive, Research Triangle Park, NC 27709. 919−572−6900/800−833−3984.

Laboratory Corporation of America Holdings, 7000/800 Frontage Road, Norristown, PA 19403. (Formerly: SmithKline Beecham Clinical Laboratories, Inc., A Subsidiary of Roche Biomedical Laboratory; Roche CompuChem Laboratories, Inc., A Member of the Roche Group.)

Laboratory Corporation of America Holdings, 10788 Roselle St., San Diego, CA 92121. 800−882−7272. (Formerly: Poisonlab, Inc.)

Laboratory Corporation of America Holdings, 550 17th Ave., Suite 300, Seattle, WA 98122. 206−923−7020/800−898−0180. (Formerly: DrugProof, Division of Dynacare/Laboratory of Pathology, LLC; Laboratory of Pathology of Seattle, Inc.; DrugProof, Division of Laboratory of Pathology of Seattle, Inc.)

Laboratory Corporation of America Holdings, 1120 Main Street, Southaven, MS 38671. 866−827−8042/800−233−6339. (Formerly: LabCorp Occupational Testing Services, Inc.; MedExpress/National Laboratory Center.)

Marshfield Laboratories, Forensic Toxicology Laboratory, 1000 North Oak Ave., Marshfield, WI 54449. 715−389−3734/800−331−3734.

MAXXAM Analytics Inc., * 6740 Campobello Road, Mississauga, ONT, Canada L5N 2L8. 905−817−5700. (Formerly: NOVAMANN (Ontario), Inc.)


MetroLab-Legacy Laboratory Services, 1225 NE 2nd Ave., Portland, OR 97232. 503−413−5293/800−950−5295. Minneapolis Veterans Affairs Medical Center, Forensic Toxicology Laboratory, 1 Veterans Drive, Minneapolis, MN 55417. 612−725−2088.

National Toxicology Laboratories, Inc., 1100 California Ave., Bakersfield, CA 93304. 661−322−4250/800−350−3515. One Source Toxicology Laboratory, Inc., 1213 Genoa-Red Bluff, Pasadena, TX 77504. 888−747−3774. (Formerly: University of Texas Medical Branch, Clinical Chemistry Division; UTMB Pathology-Toxicology Laboratory.)

Oregon Medical Laboratories, P.O. Box 972, 722 East 11th Ave., Eugene, OR 97440−0972. 541−687−2134. Pacific Toxicology Laboratories, 9348 DeSoto Ave., Chatsworth, CA 91311. 800−326−6942. (Formerly: Centinela Hospital Airport Toxicology Laboratory.)

Pathology Associates Medical Laboratories, 110 West Cliff Dr., Spokane, WA 99204. 509−755−8991/800−541−7897×7. Physicians Reference Laboratory, 7800 West 110th St., Overland Park, KS 66210. 913−339−0372/800−821−3627.

Quest Diagnostics Incorporated, 3175 Presidential Dr., Atlanta, GA 30340. 770−452−1500/888−7279−6432. (Formerly: SmithKline Beecham Clinical Laboratories; SmithKline Bio-Science Laboratories).

Quest Diagnostics Incorporated, 4770 Regent Blvd., Irving, TX 75063. 800−824−6152. (Moved from the Dallas location on 03/31/01; Formerly: SmithKline Beecham Clinical Laboratories; SmithKline Bio-Science Laboratories).

Quest Diagnostics Incorporated, 4230 South Burnham Ave., Suite 250, Las Vegas, NV 89119−5412. 702−733−7886/800−413−2750. (Formerly: Associated Pathologists Laboratories, Inc.)

Quest Diagnostics Incorporated, 10101 Renner Blvd., Lenexa, KS 66219. 913−888−3927/800−873−8845. (Formerly: LabOne, Inc.; Center for Laboratory Services, a Division of LabOne, Inc.)

Quest Diagnostics Incorporated, 400 Egypt Road, Norristown, PA 19403. 610−631−4600/877−642−2216. (Formerly: SmithKline Beecham Clinical Laboratories; SmithKline Bio-Science Laboratories).

Quest Diagnostics Incorporated, 506 E. State Pkwy., Schaumburg, IL 60173. 800−669−6995/847−885−2010. (Formerly: SmithKline Beecham Clinical Laboratories; International Toxicology Laboratories).

Quest Diagnostics Incorporated, 7600 Tyrone Ave., Van Nuys, CA 91405. 818−989−2520/800−877−2520. (Formerly: SmithKline Beecham Clinical Laboratories).

Quest Diagnostics Incorporated, 2282 South Sabin Drive, Suite C, West Valley City, UT 84120. 801−606−6301/800−322−3361. (Formerly: Northwest Toxicology, a LabOne Company; LabOne, Inc., dba Northwest Toxicology; NWT Drug Testing, NorthWest Toxicology, Inc.; Northwest Drug Testing, a division of NWT Inc.)

S.E.D. Medical Laboratories, 5601 Office Blvd., Albuquerque, NM 87109. 505−727−6300/800−999−5227.

South Bend Medical Foundation, Inc., 530 N. Lafayette Blvd., South Bend, IN 46601. 574−234−4176 x276.

Southwest Laboratories. 4645 E. Cotton Center Boulevard, Suite 177, Phoenix, AZ 85040. 602−438−8507/800−279−0027.

Sparrow Health System, Toxicology Testing Center, St. Lawrence Campus, 1210 W. Saginaw, Lansing, MI 48915. 517−364−7400. (Formerly: St. Lawrence Hospital & Healthcare System).

St. Anthony Hospital Toxicology Laboratory, 1000 N. Lee St., Oklahoma City, OK 73101. 405−272−7052.

Toxicology & Drug Monitoring Laboratory, University of Missouri Hospital & Clinics, 301 Business Loop 70 West, Suite 208, Columbia, MO 65203. 573−882−1273.


US Army Forensic Toxicology Drug Testing Laboratory, 2490 Wilson St., Fort George G. Meade, MD 20755−5235. 301−677−7085.

*The Standards Council of Canada (SCC) voted to end its Laboratory Accreditation Program for Substance Abuse (LAPSA) effective May 12, 1998. Laboratories certified through that program were accredited to conduct forensic urine drug testing as required by U.S. Department of Transportation (DOT) regulations. As of that date, the certification of those accredited Canadian laboratories will continue under DOT authority. The responsibility for conducting quarterly performance testing plus periodic on-site inspections of those LAPSA-accredited laboratories was transferred to the U.S. HHS, with the HHS’ NLCP contractor continuing to have an active role in the performance testing and laboratory inspection processes. Other Canadian laboratories wishing to be considered for the NLCP may apply directly to the NLCP contractor just as U.S. laboratories do.

Upon finding a Canadian laboratory to be qualified, HHS will recommend that DOT certify the laboratory (Federal Register, July 16, 1996) as meeting the minimum standards of the Mandatory Guidelines published in the Federal Register on April 13, 2004 (69 FR
The applicant requests a permit to take (harass by survey, capture, handle, collar, take blood samples, relocate, sacrifice, and release) the gray wolf (Canis lupus) in conjunction with wolf management activities in the State of Idaho north of Interstate 90, for the purpose of enhancing its survival.

The applicant proposes to: (a) Conduct monitoring of wolf populations; and (b) coordinate non-lethal and lethal control actions to reduce wolf conflicts with livestock and dogs. These actions are currently coordinated by the U.S. Fish and Wildlife Service (Service). If the permit is issued, the applicant would take on responsibility for managing wolves in northern Idaho. Wolf management activities would be in accordance with the requirements of the State of Idaho Wolf Conservation and Management Plan (March 2002) and the Service’s Interim Wolf Control Plan for Northwestern Montana and the Panhandle of Northern Idaho (Control Plan) (September 1999).

If issued, the permit would not affect ongoing wolf management in the remainder of the State of Idaho conducted in accordance with the non-essential experimental population regulations found at 50 CFR 17.84(a).

We have determined that a practical, responsive management program is essential to enhancing survival of the wolf in the wild (Service 1987; Service 1994; Service 1999). The program must respond to wolf-livestock conflicts, while promoting wolf recovery objectives. The Control Plan provides guidelines for: (a) Determining problem wolf status (including investigative procedures and criteria), (b) conducting wolf control actions, and (c) disposition of problem wolves.

We have made a preliminary determination that issuance of this permit would be categorically excluded from further consideration under the National Environmental Policy Act of 1969 (NEPA). If issued, the permit would authorize Idaho Department of Fish and Game to manage wolves in the same manner that the Service has in the 6 years since the Control Plan was adopted for northern Idaho. No additional environmental impacts would be expected beyond those analyzed in the Service’s 1988 Environmental Assessment, the Service’s 1999 Environmental Action Memorandum, and the Control Plan. The effect of the permit would be to allow continuation of previously analyzed and authorized activities; therefore, its issuance would be an administrative action.